Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Microsoft

Novartis and Microsoft test Kinect MS tool

The partners have a proof-of-concept for a system that could measure the condition's symptoms

- PMLiVE

Astellas sells dermatology unit to Leo for €675m

Continuesthe company's restructuring drive

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

Will boost its pipeline prospects and inhaled device capabilities

Microsoft to back new wave of health startups

Technology giant's venture arm partners with Becton Dickinson on new programme

Novartis building

Novartis’ dermatology plans advance with Xolair approval

Green light for use in chronic spontaneous urticaria

- PMLiVE

Almirall expands in US via $400m deal to buy Aqua

Will boost its standing in dermatology

- PMLiVE

Forest and Almirall delay FDA filing of COPD drug

Puts companies behind in LAMA/ LABA combination race

- PMLiVE

Almirall launches Sativex in Italy

Brings cannabis-based drug for multiple sclerosis spasticity to market

- PMLiVE

Merz pulls out of race for Obagi Medical

Leaves Valeant open to complete takeover

- PMLiVE

Battle lines drawn as Valeant ups Obagi bid

Hits back against Merz offer

- PMLiVE

Merz offers $385m to trump Valeant’s bid for Obagi

Could spark bidding war for dermatology specialist

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links